- Report
- July 2026
- 287 Pages
Global
From €5304EUR$5,850USD£4,533GBP
- Report
- July 2026
- 291 Pages
Global
From €5304EUR$5,850USD£4,533GBP
- Report
- July 2026
- 276 Pages
Global
From €5304EUR$5,850USD£4,533GBP
- Report
- July 2026
- 196 Pages
Global
From €5304EUR$5,850USD£4,533GBP
- Report
- February 2026
- 250 Pages
Global
From €4071EUR$4,490USD£3,479GBP
- Report
- February 2026
- 250 Pages
Global
From €4071EUR$4,490USD£3,479GBP
- Report
- July 2026
- 274 Pages
Global
From €5304EUR$5,850USD£4,533GBP
- Report
- May 2026
- 150 Pages
Global
From €2447EUR$2,699USD£2,092GBP
- Report
- April 2026
- 180 Pages
Global
From €4307EUR$4,750USD£3,681GBP
- Report
- October 2025
- 160 Pages
Global
From €2865EUR$3,160USD£2,449GBP
€3581EUR$3,950USD£3,061GBP
- Report
- October 2025
- 160 Pages
Global
From €2865EUR$3,160USD£2,449GBP
€3581EUR$3,950USD£3,061GBP
- Report
- April 2026
- 91 Pages
Global
From €3500EUR$4,135USD£3,096GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,135USD£3,096GBP
- Report
- September 2025
- 140 Pages
Global
From €4397EUR$4,850USD£3,758GBP
- Report
- May 2024
- 391 Pages
Global
From €5268EUR$6,013USD£4,350GBP
- Report
- November 2024
- 100 Pages
Global
From €5395EUR$5,950USD£4,611GBP
- Report
- May 2024
- 200 Pages
Global
From €3763EUR$4,150USD£3,216GBP
- Report
- September 2021
- 111 Pages
Global
From €4080EUR$4,500USD£3,487GBP
- Report
- October 2022
- 270 Pages
Global
From €3400EUR$3,750USD£2,906GBP
- Report
- January 2025
- 375 Pages
Global
From €4533EUR$5,000USD£3,875GBP

Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms.
Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections.
The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more